Knox, Jennifer

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 2,479

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,789

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial

Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,273

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 1,092

Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution

Chan-Seng-Yue, M., Kim, J. C., Wilson, G. W., Ng, K., Figueroa, E. F., O’Kane, G. M., Connor, A. A., Denroche, R. E., Grant, R. C., McLeod, J., et al. (2020) · Nature Genetics

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 669

Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial

Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 618

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

Spatially confined sub-tumor microenvironments in pancreatic cancer

Grünwald, B. T., Devisme, A., Andrieux, G., Vyas, F., Aliar, K., McCloskey, C. W., Macklin, A., Jang, G. H., Denroche, R., Romero, J. M., et al. (2021) · Cell

Pancreatic and Hepatic Oncology ResearchSingle-cell and spatial transcriptomics

Cited by 433

GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer

O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., et al. (2020) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchBreast Cancer Treatment Studies

Cited by 352

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., Master, V. A., Pal, S. K., Miller, W. H., Karsh, L. I., et al. (2015) · Journal for ImmunoTherapy of Cancer

Renal cell carcinoma treatmentImmunotherapy and Immune Responses

Cited by 205

A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer

Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 146

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Melero, I., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., Kudo, M., Hou, M.-M., Matilla, A., Tovoli, F., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 101

Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival

Spreafico, A., Coate, L., Zhai, R., Xu, W., Chen, Z.-F., Chen, Z., Patel, D., Tse, B., Brown, M. C., Heist, R. S., et al. (2017) · Cancer Epidemiology

Esophageal Cancer Research and TreatmentHead and Neck Cancer Studies

Cited by 19

PASS-01: pancreatic adenocarcinoma signature stratification for treatment–01

Knox, J. J., Jaffee, E. M., O'Kane, G. M., Plenker, D., Zhang, A., Ramotar, S., Dodd, A., Prince, R. M., Laheru, D., Yu, K. H., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 17